Carbone called BAP1 a “paradox” because of its seeming ability to both promote and slow cancer, depending on the ...
The study published in NEJM entitled, “Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors,” highlighted the antitumor activity of rezatapopt in heavily pretreated patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results